This registry is a multi-center, prospective, longitudinal, observational program that will gather and analyse data on participants treated with infliximab, golimumab, golimumab Intravenous (I.V) or ustekinumab. Treatment will be prescribed by the physician according to actual clinical practice or standard of care for Rheumatoid Arthritis (RA), Axial Spondyloarthritis (AxSpA) , Psoriatic Arthritis (PsA); there will be no randomized assignments to treatment. At baseline and approximately every 6 months thereafter, information will be collected to assess safety, clinical outcomes, quality of life, comorbidities, pharmacoeconomics and treatment regimens among cohorts of participants receiving infliximab, golimumab, golimumab I.V or ustekinumab for the treatment of RA, AxSpA and PsA.
Participants will be selected for this registry using a non-probability sampling method.
Study Type
OBSERVATIONAL
Enrollment
2,821
Unnamed facility
Montreal, Quebec, Canada
Disease Status of Canadian Participants With Rheumatic Disease Treated With Infliximab
Physician will rate arthritis activity using Visual Analog Scale (VAS) ranging from 0 to 100; higher scores indicated greater affectation due to disease activity.
Time frame: Up to 4 years
Disease Status of Canadian Participants With Rheumatic Disease Treated With Golimumab
Physician will rate arthritis activity using VAS ranging from 0 to 100; higher scores indicated greater affectation due to disease activity.
Time frame: Up to 4 years
Disease Status of Canadian Participants With Rheumatic Disease Treated With Golimumab Intravenous (I.V)
Physician will rate arthritis activity using VAS ranging from 0 to 100; higher scores indicated greater affectation due to disease activity.
Time frame: Up to 4 years
Disease Status of Canadian Participants With Rheumatic Disease Treated With Ustekinumab
Physician will rate arthritis activity using VAS ranging from 0 to 100; higher scores indicated greater affectation due to disease activity.
Time frame: Up to 4 years
The Number of Participants With Adverse Events
Time frame: Up to 4 years
Expanded Information and Support for Healthcare Providers and Hospitals About the Appropriate use of Infliximab
Provides expanded data to health care providers and hospitals to estimate and support appropriate use of Infliximab.
Time frame: Up to 4 years
Expanded Information and Support for Healthcare Providers and Hospitals About the Appropriate use of Golimumab
Provides expanded data to health care providers and hospitals to estimate and support appropriate use of Golimumab.
Time frame: Up to 4 years
Expanded Information and Support for Healthcare Providers and Hospitals About the Appropriate use of Golimumab I.V
Provides expanded data to health care providers and hospitals to estimate and support appropriate use of Golimumab I.V.
Time frame: Up to 4 years
Expanded Information and Support for Healthcare Providers and Hospitals About the Appropriate use of Ustekinumab
Provides expanded data to health care providers and hospitals to estimate and support appropriate use of Ustekinumab.
Time frame: Up to 4 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.